David DiBardino, MD, explains how intratumoral radioenhancer therapy works, why standardization remains a challenge, and what early CONVERGE study data suggest for locally advanced NSCLC.
Feature|Articles|February 18, 2026
Precision Oncology and the New Era of Lung Cancer
Author(s)Sabrina Serani, Bruna Pellini, MD
Fact checked by: Andrea Eleazar, MHS
Discover how precision lung cancer care tackles gene fusions, new HER2/ROS1/ALK drugs, expanded screening, and liquid biopsies shaping 2026 treatment.
Advertisement
Advertisement
The landscape of thoracic oncology has undergone a seismic shift over the last 2 decades. Where once a diagnosis of advanced lung cancer offered few paths forward, the advent of precision medicine has transformed the field into one of the most dynamic areas of modern medicine. Bruna Pellini, MD, chief of Thoracic Medical Oncology at Baptist Health Miami Cancer Institute, specializes in treating uncommon mutations and discussed how to navigate the increasingly complex web of targeted therapies.
Related to this article
A single blood draw 3 to 9 weeks into immunotherapy predicted survival outcomes in metastatic non–small cell lung cancer, according to a new Johns Hopkins study.
Jonathan Villena-Vargas, MD, explains how a subcostal robotic approach avoids intercostal nerve damage, cutting pain post thoracotomy and reducing opioid use.
The COPERNICUS study of amivantamab/lazertinib showed lower rates of adverse events and discontinuation with supportive care regimens in patients with EGFR-mutated non–small cell lung cancer.
The FDA approved an sNDA updating the taletrectinib label with a 49.7-month median duration of response from TRUST-I in ROS1-positive NSCLC.
KEYNOTE-D46 shows sacituzumab govitecan plus pembrolizumab misses PFS/OS targets in PD-L1–high metastatic NSCLC, despite higher responses and toxicity.
The phase 3 DESTINY-Lung04 trial showed first-line trastuzumab deruxtecan extended PFS in patients with HER2-mutant NSCLC.
Updated PRESERVE-003 data showed gotistobart nearly doubled median OS vs docetaxel in previously treated squamous NSCLC.
Advertisement
Advertisement